Virus Research,
Год журнала:
2024,
Номер
351, С. 199507 - 199507
Опубликована: Дек. 13, 2024
Chronic
hepatitis
B
(CHB)
is
a
significant
global
health
issue
affecting
approximately
254
million
individuals
worldwide.
Achieving
the
loss
of
surface
antigen
(HBsAg),
either
with
or
without
seroconversion
to
antibody
(HBsAb),
regarded
as
functional
cure
and
optimal
goal
for
addressing
CHB,
can
be
achieved
through
various
approaches,
including
induction
nucleos(t)ide
analogues
(NAs),
pegylated
interferon
alpha
(PegIFNα),
spontaneous
clearance
HBsAg.
Spontaneous
HBsAg
rare,
while
NAs
directly
inhibit
HBV
DNA,
they
are
unable
act
on
covalently
closed
circular
DNA
(cccDNA),
hence
inhibiting
production
clearing
extremely
challenging.
On
other
hand,
based
PegIFNα
shows
good
long-term
durability,
but
over
10
%
patients
still
experience
relapse,
mostly
within
48
weeks
after
cure.
Factors
related
CHB
antiviral
therapy
complex,
host
factors,
viral
environmental
etc.
The
integration
into
liver
cells,
persistence
cccDNA,
insufficient
cell
responses
compromised
T
function
pose
barriers
clearance.
Therefore,
this
study
systematically
reviewed
relevant
factors
potential
mechanisms
influencing
which
provide
basis
personalized
treatment,
help
predict
treatment
outcomes
assess
prognosis,
theoretical
support
advancement
novel
strategies
medications.
Liver Cancer,
Год журнала:
2024,
Номер
unknown, С. 1 - 17
Опубликована: Июнь 21, 2024
Our
previous
nested-case-control
study
demonstrated
elevated
adiponectin
increased
liver
cirrhosis
and
HCC
risk
in
HBV
carriers.
We
extended
the
analysis
to
whole
REVEAL-HBV
cohort
prospectively
evaluate
whether
directly
affected
end-stage
diseases,
or
through
affecting
progression.
Baseline
plasma
was
determined
investigate
association
between
subsequent
HBeAg,
HBsAg,
DNA
seroclearance,
development
of
cirrhosis,
liver-related
death.
Whether
characteristics
modify
adiponectin-milestones
associations
also
examined.
Among
3,931
HBsAg(+)/anti-HCV(-)
participants,
3,684
had
sufficient
biosamples
left
for
assay.
Elevated
associated
with
a
higher
chance
HBeAg-seropositive,
high
viral
load
(≥2
×
105
IU/mL)
HBsAg
titers
(≥1,000
dose-response
manner
(OR
=
2.25,
95%
CI:
1.55-3.28;
OR
2.11,
1.47-3.04;
1.92,
1.47-2.52
Q5
vs.
Q1,
respectively).
Those
highest
quintile
lower
achieving
HBeAg
(HR
0.48,
0.27-0.85),
0.69,
0.49-0.97),
seroclearance
0.63,
0.43-0.90)
developing
2.88,
1.98-4.20,
2.38,
1.52-3.73),
died
from
causes
2.32,
1.51-3.54).
genotype
significantly
modified
adiponectin-HCC
(Pinteraction
0.005)
adiponectin-liver
death
0.0157),
among
C.
is
consistently
all
important
chronic
infection
milestones
toward
progression
cancer.
The
exact
mechanism
how
mediates
carcinogenesis
remains
unclear
warrants
further
investigation.
Disentangling
this
may
help
us
finding
new
treatment
target,
biomarker
surveillance
identify
high-risk
patients,
even
cancer
prevention.
Abstract
Background
Steatotic
liver
disease
(SLD)
is
an
emerging
that
has
been
associated
with
increased
risk
for
hepatocellular
carcinoma
(HCC).
The
impact
of
concurrent
SLD
on
the
prognosis
HCC
remains
unknown.
This
study
investigates
how
affects
outcomes
patients
undergoing
curative
radiofrequency
ablation
(RFA)
therapy.
Methods
A
retrospective
analysis
early‐stage
receiving
RFA
at
a
tertiary
medical
center
was
conducted.
Laboratory
data
and
characteristics
were
recorded
analyzed
by
Cox
proportional
hazards
regression
model
to
predict
recurrence
all‐cause
mortality
after
RFA.
Results
total
598
included
between
2005
2015,
139
459
classified
in
non‐SLD
groups,
respectively.
group
exhibited
significantly
better
reserve
lower
cumulative
incidence
liver‐related
median
follow‐up
51
months.
After
adjusting
metabolic
dysfunction,
reserve,
characteristics,
presence
reduced
(adjusted
hazard
ratio
[aHR],
0.67;
95%
confidence
interval
[CI],
0.45–0.996;
p
=
.048),
which
supported
inverse
probability
weighting
(aHR,
0.65;
CI,
0.42–1.00;
.049).
Poor
functional
(high
albumin‐bilirubin
grades)
dose
dependently.
Barcelona
Clinic
Liver
Cancer
staging
higher
Fibrosis‐4
index
predictors
recurrence,
whereas
not.
Conclusions
Among
RFA,
those
had
compared
poor
reserve.
Plain
Language
Summary
present
research
demonstrated
both
cancer
steatotic
who
received
survived
longer
without
disease.
Maintaining
good
function
important
prognostic
factor
survival.
American Journal of Cancer Research,
Год журнала:
2024,
Номер
14(9), С. 4567 - 4579
Опубликована: Янв. 1, 2024
In
2023,
a
new
nomenclature,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
replaced
the
term
non-alcoholic
fatty
(NAFLD).
With
global
rise
in
MASLD
prevalence,
concurrent
and
chronic
hepatitis
B
(CHB)-related
hepatocellular
carcinoma
(HCC)
are
becoming
increasingly
common.
This
study
aimed
to
evaluate
clinical
impact
of
on
long-term
survival
outcomes
patients
with
CHB-related
early-stage
HCC
following
curative
resection.
retrospective
included
diagnosed
who
underwent
hepatectomy
between
January
2010
December
2019.
We
examined
association
histologically
confirmed
outcomes,
overall
(OS)
recurrence-free
(RFS)
calculated
using
Kaplan-Meier
method
compared
log-rank
test.
Of
587
eligible
patients,
275
(46.8%)
were
MASLD.
Patients
had
higher
prevalence
diabetes,
hypertension,
body
mass
index
(BMI)
>
23
kg/m
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Ноя. 11, 2024
While
previous
reports
have
shown
that
hepatitis
B
virus
(HBV)
infection
affects
lipid
metabolism
and
vice
versa,
the
impact
of
dyslipidemia
on
functional
cure
HBV
following
peginterferon
alfa
(PegIFNα)
therapy
remains
unknown.
Hence,
this
study
aimed
to
investigate
effect
surface
antigen
(HBsAg)
clearance
develop
a
nomogram
model
for
predicting
patients
whom
PegIFNα
is
indicated.
A
total
160
nucleos(t)ide
analogues
(NAs)-
experienced
chronic
(CHB)
treated
with
(180
µg/week)
were
enrolled
in
study.
The
relationship
between
serum
HBsAg
was
analysed.
Univariate
multivariate
COX
analyses
used
construct
plot
model.
area
under
receiver
operating
characteristic
curve
(AUC)
calibration
evaluate
discrimination
model,
respectively.
After
48
weeks
therapy,
33
cohort
achieved
clearance.
indicated
significantly
associated
an
independent
predictor
(HR
=
0.243,
P
0.001).
Kaplan-Meier
survival
show
cumulative
higher
normolipidemic
group
than
(log-rank
test,
0.007).
During
treatment,
triglyceride
showed
increasing
trend,
while
levels
cholesterol,
high-density
lipoprotein,
low-density
apolipoprotein
A1
decreased.
Dyslipidemia
other
indicators
independently
AUC
at
36-week
48-week
0.879
0.856,
demonstrated
good
calibration.
can
affect
antiviral
efficacy
NAs-experienced
CHB
patients.
Our
findings
suggest
constructed
using
has
predictive
power
may
help
physicians
identify
superior
therapy.
Virus Research,
Год журнала:
2024,
Номер
351, С. 199507 - 199507
Опубликована: Дек. 13, 2024
Chronic
hepatitis
B
(CHB)
is
a
significant
global
health
issue
affecting
approximately
254
million
individuals
worldwide.
Achieving
the
loss
of
surface
antigen
(HBsAg),
either
with
or
without
seroconversion
to
antibody
(HBsAb),
regarded
as
functional
cure
and
optimal
goal
for
addressing
CHB,
can
be
achieved
through
various
approaches,
including
induction
nucleos(t)ide
analogues
(NAs),
pegylated
interferon
alpha
(PegIFNα),
spontaneous
clearance
HBsAg.
Spontaneous
HBsAg
rare,
while
NAs
directly
inhibit
HBV
DNA,
they
are
unable
act
on
covalently
closed
circular
DNA
(cccDNA),
hence
inhibiting
production
clearing
extremely
challenging.
On
other
hand,
based
PegIFNα
shows
good
long-term
durability,
but
over
10
%
patients
still
experience
relapse,
mostly
within
48
weeks
after
cure.
Factors
related
CHB
antiviral
therapy
complex,
host
factors,
viral
environmental
etc.
The
integration
into
liver
cells,
persistence
cccDNA,
insufficient
cell
responses
compromised
T
function
pose
barriers
clearance.
Therefore,
this
study
systematically
reviewed
relevant
factors
potential
mechanisms
influencing
which
provide
basis
personalized
treatment,
help
predict
treatment
outcomes
assess
prognosis,
theoretical
support
advancement
novel
strategies
medications.
